Asset profile
Tremelimumab
Monoclonal antibody
Approvedregulatory verdict
Evidence outlook
Approved: Non-Small Cell Lung Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
63 competitors in this universe: 3 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Tremelimumab: this drug | Approved | Monoclonal antibody | CTLA-4 | ||
| Botensilimab | Phase 3 | Monoclonal antibody | CTLA-4 | ||
| Gotistobart | Phase 3 | Monoclonal antibody | CTLA-4 | ||
| BA3071 | Phase 1/2 | Biologic (subtype unspecified) | CTLA-4 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET |
…and 48 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(50 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (12)
October 2026 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-10-23 · NCT06008093 · CT.gov ↗
What to watch
November 2026 (5)
Phase 1/2Esophageal Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2026-11 · NCT02962063 · CT.gov ↗
What to watch
Phase 2Germ Cell Tumor, Nonseminomatous Germ Cell Tumor, Seminoma, Germinomatous Germ Cell Tumor, Dysgerminoma, Pineal Germ Cell TumorActive not recruiting
Est. primary completion 2026-11 · NCT03158064 · CT.gov ↗
What to watch
Phase 2Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 …Recruiting
Est. primary completion 2026-11-13 · NCT07174570 · CT.gov ↗
What to watch
Phase 1Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma …Recruiting
Est. primary completion 2026-11-30 · NCT06058663 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2026-11-30 · NCT07081633 · CT.gov ↗
What to watch
December 2026 (6)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT05000710 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT04585490 · CT.gov ↗
What to watch
Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT03606967 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05844046 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06698250 · CT.gov ↗
What to watch
Phase 2Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT03937830 · CT.gov ↗
What to watch
2027 (18)
January 2027 (2)
Phase 1Solid Tumor, Adult, Malignant Solid Tumor, Stomach Adenocarcinoma, Esophageal AdenocarcinomaRecruiting
Est. primary completion 2027-01 · NCT06824363 · CT.gov ↗
What to watch
Phase 2Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8Active not recruiting
Est. primary completion 2027-01-31 · NCT03601455 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02 · NCT04499053 · CT.gov ↗
What to watch
Phase 1BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma …Active not recruiting
Est. primary completion 2027-02-23 · NCT04605731 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Advanced Unresectable Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-04 · NCT07175441 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Combined Hepatocellular and CholangiocarcinomaNot yet recruiting
Est. primary completion 2027-05 · NCT06855225 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-06 · NCT05063565 · CT.gov ↗
What to watch
Phase 1Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 …Recruiting
Est. primary completion 2027-06-01 · NCT04005690 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaRecruiting
Est. primary completion 2027-06-25 · NCT06796114 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Hepatocellular Carcinoma Non-resectable, HCCActive not recruiting
Est. primary completion 2027-07-31 · NCT04522544 · CT.gov ↗
What to watch
August 2027 (3)
Phase 2Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8 …Not yet recruiting
Est. primary completion 2027-08-01 · NCT07511504 · CT.gov ↗
What to watch
Phase 2ImmunotherapyActive not recruiting
Est. primary completion 2027-08-10 · NCT04169841 · CT.gov ↗
What to watch
Phase 1Solid TumoursRecruiting
Est. primary completion 2027-08-30 · NCT07391670 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2HCC - Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-09-27 · NCT06045975 · CT.gov ↗
What to watch
October 2027 (2)
December 2027 (2)
Phase 1Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-12 · NCT06710223 · CT.gov ↗
What to watch
Phase 1Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT02812420 · CT.gov ↗
What to watch
2028 (9)
January 2028 (2)
March 2028 (1)
Phase 1/2Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-03-31 · NCT06911255 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1/2MesotheliomaRecruiting
Est. primary completion 2028-05-31 · NCT05932199 · CT.gov ↗
What to watch
June 2028 (1)
Phase 1/2Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal CancerRecruiting
Est. primary completion 2028-06-30 · NCT03539822 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 …Recruiting
Est. primary completion 2028-07-31 · NCT04430452 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8Recruiting
Est. primary completion 2028-10-08 · NCT07288034 · CT.gov ↗
What to watch
2029 (4)
March 2029 (2)
Phase 1Biliary Tract CancersRecruiting
Est. primary completion 2029-03 · NCT06564623 · CT.gov ↗
What to watch
Phase 3Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8Recruiting
Est. primary completion 2029-03-10 · NCT07166406 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2HCC, Tace, ImmunotherapyNot yet recruiting
Est. primary completion 2029-08-14 · NCT07168668 · CT.gov ↗
What to watch
September 2029 (1)
Phase 2/3Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-09-14 · NCT06904170 · CT.gov ↗
What to watch
2030 (6)
January 2030 (1)
Phase 2Hepatocellular Carcinoma Non-resectableRecruiting
Est. primary completion 2030-01-02 · NCT07122089 · CT.gov ↗
What to watch
March 2030 (1)
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-03-15 · NCT06921785 · CT.gov ↗
What to watch
April 2030 (2)
May 2030 (2)
Phase 2HCC - Hepatocellular Carcinoma, Tremelimumab, Durvalumab, RadiotherapyRecruiting
Est. primary completion 2030-05-31 · NCT06999707 · CT.gov ↗
What to watch
Phase 2HCC - Hepatocellular Carcinoma, Durvalumab, Tremelimumab, Proton RadiotherapyRecruiting
Est. primary completion 2030-05-31 · NCT06999694 · CT.gov ↗
What to watch
2032 (1)
July 2032 (1)
Phase 2Colorectal Cancer, Endometrial CancerRecruiting
Est. primary completion 2032-07-01 · NCT06680739 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.